| Literature DB >> 31341502 |
Yue Luo1,2, Le Kuai1,2, Ningjing Song3, Xiaojie Ding1, Xiaoying Sun2, Ying Luo1, Yi Ru1, Seokgyeong Hong1, Meng Xing1, Mi Zhou1, Bin Li1,2,4, Xin Li1,2.
Abstract
In this quantitative study, we evaluated the effectiveness and safety of fire needle therapy for nodular prurigo. We systematically searched several databases, including EMBASE, PubMed, the Cochrane Library, the Web of Science, the China Network Knowledge Infrastructure, the Wanfang Data Knowledge Service Platform, and the China Science and Technology Journal Database, and retrieved randomized controlled trials comparing conventional therapies (control group) with fire needle therapy alone or in combination with conventional therapies. Revman 5.2 software was used to calculate risk ratios (RR) with 95% confidence intervals (CI). In total, 14 trials with 1176 participants were included. Our quantitative study showed that the effectiveness rate of fire needle therapy combined with conventional therapies was significantly higher than that of conventional therapies alone (fire needle + traditional Chinese medicine [TCM] vs. TCM: RR, 1.11; 95% CI, 1.04 to 1.18; fire needle + oral thalidomide + topical glucocorticoid [TGC] vs. thalidomide + TGC: RR, 1.41; 95% CI, 1.17 to 1.70; fire needle + TGC vs. TGC only: RR, 1.18; 95% CI, 1.07 to 1.31). Similar results were obtained for the Symptom Score Reducing Index (fire needle + TCM vs. TCM: mean difference [MD], -3.39; 95% CI: -5.39 to -1.39), visual analog scale scores for itching severity (fire needle vs. halometasone cream: MD, -0.93; 95% CI, -1.29 to -0.58; fire needle + TCM vs. TCM: MD, -1.18; 95% CI, -1.78 to -0.58), and Dermatology Life Quality Index (fire needle vs. halometasone cream: MD, -3.03; 95% CI, -3.43 to -2.63; fire needle + TCM vs. TCM: MD, -2.53; 95% CI, -3.12 to -1.94). Adverse event and recurrence rates were comparable between groups. Thus, fire needle therapy alone or combined with conventional treatments may be effective for nodular prurigo, without any additional side effects.Entities:
Year: 2019 PMID: 31341502 PMCID: PMC6614990 DOI: 10.1155/2019/8797056
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1Study selection process for a quantitative study on the safety and efficacy of fire needle therapy for nodular prurigo.
Figure 2Risk of bias in the studies included in a quantitative study on the safety and efficacy of fire needle therapy for nodular prurigo. (a) Risk of bias graph. (b) Risk of bias summary.
Figure 3Forest plot comparing effectiveness rates between fire needle and control groups in a quantitative study on the safety and efficacy of fire needle therapy for nodular prurigo.
Figure 4Forest plot comparing effectiveness rates between control treatments and fire needle therapy combined with other treatments in a quantitative study on the safety and efficacy of fire needle therapy for nodular prurigo.
Figure 5Forest plot comparing Symptom Score Reducing Index (SSRI) scores between fire needle and control groups in a quantitative study on the safety and efficacy of fire needle therapy for nodular prurigo.
Figure 6Forest plot comparing visual analog scale (VAS) scores for itching severity between fire needle and control groups in a quantitative study on the safety and efficacy of fire needle therapy for nodular prurigo.
Figure 7Forest plot comparing Dermatology Life Quality Index (DLQI) scores between fire needle and control groups in a quantitative study on the safety and efficacy of fire needle therapy for nodular prurigo.
Figure 8Forest plot comparing recurrence rate rates between fire needle and control groups in a quantitative study on the safety and efficacy of fire needle therapy for nodular prurigo.
Figure 9Forest plot comparing adverse events between fire needle and control groups in a quantitative study on the safety and efficacy of fire needle therapy for nodular prurigo.
| Study | Location | Baseline data comparable | Disease duration (average) | Average age (years) | Course of treatment (weeks) | Sample Size | FUP (months) | Adverse events | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | C | E | C | E | C | E | C | |||||
| Qu Y, 2014 | China | Yes | 10.7 (6.1) y | 10.7 (6.1) y | 54.6 (16.5) | 54.6 (16.5) | 8 | 35 | 34 | NR | Pain (2) | 0 |
|
| ||||||||||||
| Yang SQ, 2014 | China | Yes | NR | NR | NR | NR | 4 | 61 | 60 | NR | NR | NR |
|
| ||||||||||||
| Li B, 2015 | China | Yes | 2 y | 2 y | 40 | 40 | 4 | 40 | 40 | NR | Erythema and swelling (5) | 0 |
|
| ||||||||||||
| Zhang JB, 2015 | China | Yes | 5.63 (3.22) y | 5.78(3.12) y | 23.42(4.51) | 22.9(5.12) | 4 | 49 | 46 | 6 | Pain (5) | Blister (27) |
|
| ||||||||||||
| Wang JZ, 2015 | China | Yes | 6.78 (3.6) y | 6(3.29) y | 32.91(6.91) | 31.09(5,21) | 4 | 37 | 38 | NR | NR | NR |
|
| ||||||||||||
| Pan HY, 2015 | China | Yes | 6 (2.85) m | 5.91 (2.64) m | 34.94(5.79) | 35.06(6.19) | 8 | 34 | 34 | NR | Dizziness (1) | Irregular menstruation (1), stomach ache (1) |
|
| ||||||||||||
| Zhao JL, 2016 | China | Yes | 18 m | 18 m | 41 | 41 | 4 | 28 | 24 | NR | Thirst (2), drowsiness (2), erythema and swelling (1) | Thirst (2), drowsiness (3) |
|
| ||||||||||||
| Chen XM, 2016 | China | Yes | 3.62 (1.55) y | 3.51 (1.95) y | 31.22 (5.64) | 31.42 (5.27) | 4 | 32 | 31 | 3m | Pain (2), pruritus with skin bruises (1) | Dizziness (1) |
|
| ||||||||||||
| Li GF, 2017 | China | Yes | 5.1 (2.2) y | 5.2 (2) y | 40.3 (2.3) | 42.1 (2.0) | 4 | 40 | 40 | 6m | NR | NR |
|
| ||||||||||||
| Wang J, 2017 | China | Yes | 2–8 y | 2–8 y | 38 | 38 | 4 | 50 | 50 | NR | NR | NR |
|
| ||||||||||||
| Liu M, 2017 | China | Yes | 9.23 (2.19) m | 9.56 (2.36) m | 39.88 (3.36) | 38.98 (3.69) | 4 | 25 | 25 | NR | NR | NR |
|
| ||||||||||||
| Mei CF, 2017 | China | Yes | 20.67 (10.28) m | 18.63 (9.43) m | 42.1 (19.48) | 43.3 (14.38) | 8 | 30 | 30 | NR | Dizziness (2) | Thirst (2), drowsiness (3) |
|
| ||||||||||||
| Deng QF, 2018 | China | Yes | 4.57 (1.6) y | 4.23 (1.56) y | 38.41 (4.62) | 37.56 (4.56) | 4 | 34 | 34 | NR | NR | NR |
|
| ||||||||||||
| Hu FM, 2018 | China | Yes | 2 (2.3) y | 2 (2.5) y | 35 (8.8) | 38 (8.2) | 4 | 60 | 60 | NR | Erythema and swelling (2) | 0 |
E: experimental group (fire needle therapy alone or combined with conventional therapy), C: control group (only the conventional therapy used in the experimental group), NR: no report, FUP: follow-up period, T: true, RCT: randomized controlled trial, w: weeks, m: months, y: years, SSRI: Symptom Score Reducing Index, VAS: visual analog scale, DLQI: Dermatology Life Quality Index, RER: recurrence rate, and AEs: adverse events.
| Study | RCT | Recurrence | Interventions | Main outcomes | ||
|---|---|---|---|---|---|---|
| E | C | E | C | |||
| Qu Y, 2014 | T | NR | NR | Fire needle/fire needle + Longmu decoction | Longmu decoction | Total effectiveness rate, SSRI, AEs |
|
| ||||||
| Yang SQ, 2014 | T | NR | NR | Fire needle + Quanchong prescription | Quanchong prescription | Total effectiveness rate |
|
| ||||||
| Li B, 2015 | T | NR | NR | Fire needle/fire needle + Halometasone cream | Halometasone cream | Total effectiveness rate |
|
| ||||||
| Zhang JB, 2015 | T | 2 | 3 | Fire needle | Liquid nitrogen refrigeration | Total effectiveness rate, AEs |
|
| ||||||
| Wang JZ, 2015 | T | NR | NR | Fire needle + modified Wendan Decoction | modified Wendan decoction | Total effectiveness rate |
|
| ||||||
| Pan HY, 2015 | T | NR | NR | Fire needle + Quanchong decoction | Quanchong decoction | Total effectiveness rate SSRI, VAS, DLQI, AEs |
|
| ||||||
| Zhao JL, 2016 | T | NR | NR | Fire needle + Thalidomide +mometasone furoate | Thalidomide + mometasone furoate | Total effectiveness rate |
|
| ||||||
| Chen XM, 2016 | T | 4 | 9 | Fire needle | Halometasone cream | Total effectiveness rate, SSRI, VAS, DLQI, RER, AEs |
|
| ||||||
| Li GF, 2017 | T | 2 | 4 | Fire needle + Halometasone cream | Halometasone cream | Total effectiveness rate, RER |
|
| ||||||
| Wang J, 2017 | T | NR | NR | Fire needle + Triamcinolone acetonide injection | Triamcinolone acetonide injection | Total effective rate |
|
| ||||||
| Liu M, 2017 | T | NR | NR | Fire needle | Compound Wendan decoction | Total effectiveness rate |
|
| ||||||
| Mei CF, 2017 | T | NR | NR | Fire needle + Thalidomide | Thalidomide | Total effectiveness rate, AEs |
|
| ||||||
| Deng QF, 2018 | T | NR | NR | Fire needle | Halometasone cream | Total effectiveness rate, SSRI, VAS |
|
| ||||||
| Hu FM, 2018 | T | NR | NR | Fire needle + Quanchong decoction | Quanchong decoction | Total effectiveness rate, SSRI, AEs |
E: experimental group (fire needle therapy alone or combined with conventional therapy), C: control group (only the conventional therapy used in the experimental group), NR: no report, FUP: follow-up period, T: true, RCT: randomized controlled trial, w: weeks, m: months, y: years, SSRI: Symptom Score Reducing Index, VAS: visual analog scale, DLQI: Dermatology Life Quality Index, RER: recurrence rate, and AEs: adverse events.